Integra LifeSciences' 80% market-implied probability of beating Q3 2026 consensus estimates centers on its established pattern of adjusted EPS outperformance and margin resilience, even as preliminary guidance released October 2 showed revenue of $410–412 million below analyst targets near $416–426 million due to July flooding at its Cincinnati facility. The company guided adjusted EPS to $0.55–0.59, aligning with the $0.56–0.59 consensus range, while highlighting expected insurance offsets, improving product availability, and operating cash flow above $85 million for the quarter. This follows the Q2 beat of $0.56 versus $0.48 consensus, supported by specialty surgery growth and cost efficiencies. The October 21 earnings release remains the key near-term catalyst for resolution.